Şeyma Sehlikoğlu, Sevler Yıldız, Aslı Kazğan Kılıçaslan, Osman Kurt, Erkan Göçüm, Behice Han Almiş
{"title":"评估甲基苯丙胺和合成大麻使用障碍患者的全血细胞计数参数及其在炎症中的作用。","authors":"Şeyma Sehlikoğlu, Sevler Yıldız, Aslı Kazğan Kılıçaslan, Osman Kurt, Erkan Göçüm, Behice Han Almiş","doi":"10.5152/pcp.2024.23803","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to compare the complete blood cell count parameters of patients with methamphetamine and synthetic cannabis use disorder (MCUD), a condition that has recently exhibited a gradual increase in prevalence, with those of healthy subjects.</p><p><strong>Methods: </strong>In total, 76 patients diagnosed with MCUD and 78 healthy controls were included in the study. Venous blood samples were collected from all participants at presentation for laboratory examination.</p><p><strong>Results: </strong>The rate of mono- and poly-substance users in the patient group was 14.5% and 85.5%, respectively. The average duration of methamphetamine (METH) use in the patient group is 3.0 ± 1.9 years. White blood cell (<i>P</i> < .001), PLT (<i>P</i> = .005), monocyte count (<i>P</i> < .001), basophil count (<i>P</i> < .001), neutrophil count (<i>P</i> < .001), lymphocyte count (<i>P</i> < .001) basophil/lymphocyte ratio (BLR) (<i>P</i> = .04), SII (<i>P</i> = .006), and SIRI (<i>P</i> = .001) values were significantly higher. In contrast Hgb (<i>P</i> = .043), Hct (<i>P</i> = .002), monocyte percentage (<i>P</i> = .004), and RBC (<i>P</i> = .021) values were significantly lower in the MCUD group compared to the control group. There was a significant positive correlation between neutrophil/lymphocyte ratio and platelet/lymphocyte ratio (<i>r</i> = .552 <i>P</i> < .001) and between systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) (<i>r</i> = 0.580 <i>P</i> < .001).</p><p><strong>Conclusion: </strong>Methamphetamine and cannabis may affect the levels of inflammatory markers and SII and SIRI values through various mechanisms. To the best of our knowledge, this is the first study in the relevant literature, which investigated SII and SIRI values in patients with MCUD, therefore, the results can contribute to the future development of immune system-related markers in this field.</p>","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"34 2","pages":"134-143"},"PeriodicalIF":0.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332474/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Complete Blood Cell Count Parameters and Their Role in Inflammation in Patients with Methamphetamine and Synthetic Cannabis Use Disorder.\",\"authors\":\"Şeyma Sehlikoğlu, Sevler Yıldız, Aslı Kazğan Kılıçaslan, Osman Kurt, Erkan Göçüm, Behice Han Almiş\",\"doi\":\"10.5152/pcp.2024.23803\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The aim of this study was to compare the complete blood cell count parameters of patients with methamphetamine and synthetic cannabis use disorder (MCUD), a condition that has recently exhibited a gradual increase in prevalence, with those of healthy subjects.</p><p><strong>Methods: </strong>In total, 76 patients diagnosed with MCUD and 78 healthy controls were included in the study. Venous blood samples were collected from all participants at presentation for laboratory examination.</p><p><strong>Results: </strong>The rate of mono- and poly-substance users in the patient group was 14.5% and 85.5%, respectively. The average duration of methamphetamine (METH) use in the patient group is 3.0 ± 1.9 years. White blood cell (<i>P</i> < .001), PLT (<i>P</i> = .005), monocyte count (<i>P</i> < .001), basophil count (<i>P</i> < .001), neutrophil count (<i>P</i> < .001), lymphocyte count (<i>P</i> < .001) basophil/lymphocyte ratio (BLR) (<i>P</i> = .04), SII (<i>P</i> = .006), and SIRI (<i>P</i> = .001) values were significantly higher. In contrast Hgb (<i>P</i> = .043), Hct (<i>P</i> = .002), monocyte percentage (<i>P</i> = .004), and RBC (<i>P</i> = .021) values were significantly lower in the MCUD group compared to the control group. There was a significant positive correlation between neutrophil/lymphocyte ratio and platelet/lymphocyte ratio (<i>r</i> = .552 <i>P</i> < .001) and between systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) (<i>r</i> = 0.580 <i>P</i> < .001).</p><p><strong>Conclusion: </strong>Methamphetamine and cannabis may affect the levels of inflammatory markers and SII and SIRI values through various mechanisms. To the best of our knowledge, this is the first study in the relevant literature, which investigated SII and SIRI values in patients with MCUD, therefore, the results can contribute to the future development of immune system-related markers in this field.</p>\",\"PeriodicalId\":20847,\"journal\":{\"name\":\"Psychiatry and Clinical Psychopharmacology\",\"volume\":\"34 2\",\"pages\":\"134-143\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332474/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatry and Clinical Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5152/pcp.2024.23803\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry and Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5152/pcp.2024.23803","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Evaluation of Complete Blood Cell Count Parameters and Their Role in Inflammation in Patients with Methamphetamine and Synthetic Cannabis Use Disorder.
Background: The aim of this study was to compare the complete blood cell count parameters of patients with methamphetamine and synthetic cannabis use disorder (MCUD), a condition that has recently exhibited a gradual increase in prevalence, with those of healthy subjects.
Methods: In total, 76 patients diagnosed with MCUD and 78 healthy controls were included in the study. Venous blood samples were collected from all participants at presentation for laboratory examination.
Results: The rate of mono- and poly-substance users in the patient group was 14.5% and 85.5%, respectively. The average duration of methamphetamine (METH) use in the patient group is 3.0 ± 1.9 years. White blood cell (P < .001), PLT (P = .005), monocyte count (P < .001), basophil count (P < .001), neutrophil count (P < .001), lymphocyte count (P < .001) basophil/lymphocyte ratio (BLR) (P = .04), SII (P = .006), and SIRI (P = .001) values were significantly higher. In contrast Hgb (P = .043), Hct (P = .002), monocyte percentage (P = .004), and RBC (P = .021) values were significantly lower in the MCUD group compared to the control group. There was a significant positive correlation between neutrophil/lymphocyte ratio and platelet/lymphocyte ratio (r = .552 P < .001) and between systemic immune inflammatory index (SII) and systemic inflammation response index (SIRI) (r = 0.580 P < .001).
Conclusion: Methamphetamine and cannabis may affect the levels of inflammatory markers and SII and SIRI values through various mechanisms. To the best of our knowledge, this is the first study in the relevant literature, which investigated SII and SIRI values in patients with MCUD, therefore, the results can contribute to the future development of immune system-related markers in this field.
期刊介绍：
Psychiatry and Clinical Psychopharmacology aims to reach a national and international audience and will accept submissions from authors worldwide. It gives high priority to original studies of interest to clinicians and scientists in applied and basic neurosciences and related disciplines. Psychiatry and Clinical Psychopharmacology publishes high quality research targeted to specialists, residents and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
